Literature DB >> 22149307

Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya.

Kim C E Sigaloff1, Kishor Mandaliya, Raph L Hamers, Francis Otieno, Irene M Jao, Frederick Lyagoba, Brian Magambo, Anne Kapaata, Nicaise Ndembi, Tobias F Rinke de Wit.   

Abstract

Abstract In view of the recent antiretroviral therapy (ART) scale-up in Kenya, surveillance of transmitted HIV drug resistance (TDR) is important. A cross-sectional survey was conducted among newly HIV-1 diagnosed, antiretroviral-naive adults in Mombasa, Kenya. Surveillance drug resistance mutations (SDRMs) were identified according to the 2009 WHO list. HIV-1 subtypes were determined using REGA and SCUEAL subtyping tools. Genotypic test results were obtained for 68 of 81 participants, and SDRMs were identified in 9 samples. Resistance to nonnucleoside reverse transcriptase inhibitors (K103N) occurred in five participants, yielding a TDR prevalence of 7.4% (95% confidence interval 2.4-16.3%). Frequencies of HIV-1 subtypes were A (70.6%), C (5.9%), D (2.9%), and unique recombinant forms (20.6%). The TDR prevalence found in this survey is higher than previously reported in different regions in Kenya. These findings justify increased vigilance with respect to TDR surveillance in African regions where ART programs are scaled-up in order to inform treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22149307     DOI: 10.1089/AID.2011.0348

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  27 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.

Authors:  Michael H Chung; Ingrid A Beck; Sandra Dross; Kenneth Tapia; James N Kiarie; Barbra A Richardson; Julie Overbaugh; Samah R Sakr; Grace C John-Stewart; Lisa M Frenkel
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

3.  Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda.

Authors:  Steven J Reynolds; Victor Ssempijja; Ronald Galiwango; Anthony Ndyanabo; Gertrude Nakigozi; Fred Lyagoba; Jamirah Nazziwa; Andrew Redd; Susanna L Lamers; Ron Gray; Maria Wawer; David Serwadda; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-28       Impact factor: 2.205

4.  Prevalence of Transmitted Drug Resistance Mutations in HIV-1-Infected Drug-Naive Patients from Urban and Suburban Regions of Kenya.

Authors:  Simon Onsongo; Syed Hani Abidi; Samoel Khamadi; Reena Shah; Sheila Kageha; Peter Ojwang; Syed Ali; Nancy Okinda
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-24       Impact factor: 2.205

5.  Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.

Authors:  Rachel A Silverman; Ingrid A Beck; Catherine Kiptinness; Molly Levine; Ross Milne; Christine J McGrath; Steve Bii; Barbra A Richardson; Grace John-Stewart; Bhavna Chohan; Samah R Sakr; James N Kiarie; Lisa M Frenkel; Michael H Chung
Journal:  J Infect Dis       Date:  2017-12-19       Impact factor: 5.226

6.  Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.

Authors:  Johnson Agniswamy; John M Louis; Chen-Hsiang Shen; Sofiya Yashchuk; Arun K Ghosh; Irene T Weber
Journal:  J Med Chem       Date:  2015-06-04       Impact factor: 7.446

7.  Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

Authors:  Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

8.  Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

Authors:  Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

9.  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Yuan-Fang Wang; Arun K Ghosh; Kalapala Venkateswara Rao; Chun-Xiao Xu; Jane M Sayer; John M Louis; Irene T Weber
Journal:  J Med Chem       Date:  2013-05-01       Impact factor: 7.446

Review 10.  Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest?

Authors:  Ann M Dennis; Joshua T Herbeck; Andrew L Brown; Paul Kellam; Tulio de Oliveira; Deenan Pillay; Christophe Fraser; Myron S Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2014-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.